[Cost estimation of the treatment of acute venous syndromes with use of antiplatelet inhibitors].
The aim of research was to estimate treatment costs of platelet inhibitors and application the medicals as: salicylic acid, ticlopidynum, clopidogrel and abciximab. The analysis was based on multicenter prospective, costs study in the group of 140 patients in three varying in respect of reference degree. We conclude that the A highest costs of antiplotelet treatment associated with dicoproteins inhibitor - abciximab. Relatively low costs of antiplatelet treatment were generated in first and second reference level hospitals which do not perform PCI. In higher reference level hospitals the antiplatelet treatment costs connected with the intervention constituted 94% of total costs of pharmacotherapy.
Maciag
Agnieszka
A
Zakład Organizacji i Ekonomiki Ochrony Zdrowia oraz Szpitalnictwa, Państwowy Zakład Higieny.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016527:Drug Costs; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000191:economics*; D011044:Poland; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000191:economics*
D010975:Platelet Aggregation Inhibitors